Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis
Mehdi Hamadani(Medical College of Wisconsin), Horatiu Olteanu(Mayo Clinic in Arizona), Javier Bolaños‐Meade(Johns Hopkins University), Ernesto Ayala(Mayo Clinic in Florida), Sonali M. Smith(University of Chicago), Yi‐Bin Chen(Massachusetts General Hospital), Parameswaran Hari(Medical College of Wisconsin), Nelson J. Chao(Duke University), Gary J. Schiller(Fred Hutch Cancer Center), Alessandro Digilio, Ronald E. Gress(National Institutes of Health), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Niels Smedegaard Anderson(Rigshospitalet), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Jong Wook Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Jean A. Yared(University of Maryland, Baltimore), Umar Farooq(Wake Forest University), Kwang Woo Ahn(Medical College of Wisconsin)
Cited by 43
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k